Browse Articles

Discover research articles across all indexed journals

The prevalence and associated risk factors of primary dysmenorrhea among women in Beijing: a cross-sectional study

Scientific Reports Yi-Ling Wang, Hong-Lan Zhu Feb 10, 2025 DOI: 10.1038/s41598-025-89038-5

AI-driven prediction of prostate cancer risk: A comparative analysis with C the Signs in the Mayo Clinic data platform.

Journal of Clinical Oncology Bea Bakshi, Sana Raoof, Tufia C. Haddad et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.371

371 Background: Prostate cancer is the most common malignancy in men globally and remains among the top five leading causes of cancer-related deaths. Emerging evidence suggests that early identification of symptoms can detect localized disease thus enabling opportunities for curative intent treatments. This study evaluates the use of the AI-powered prediction model, C the Signs, to passively screen for prostate cancer by leveraging data from electronic medical records (EMRs), offering a novel pathway for identifying high-risk individuals. Methods: A retrospective analysis was conducted using the Mayo Data Platform, encompassing 418,477 male patient records, of which 16,835 were diagnosed with prostate cancer. C the Signs identified patients at risk based solely on their EMR data, utilizing AI-driven pattern recognition. Sensitivity and specificity analyses were performed to assess the prediction model’s accuracy. Additionally, we examined the time-to-diagnosis advantage for patients flagged by the model compared to traditional physician clinical diagnoses. Results: C the Signs demonstrated a sensitivity of 83.3% and a specificity of 52.5% for identifying patients at risk of prostate cancer. Notably, 31.8% of prostate cancer cases were identified at risk up to five years earlier by the model compared to traditional physician clinical diagnosis. Conclusions: The integration of AI-driven prediction models like C the Signs into prostate cancer screening pathways provides an opportunity to enhance early detection, particularly in symptomatic individuals. Compared to prostate-specific antigen (PSA) testing, the model achieved equivalent sensitivity and 38% higher specificity, positioning it as a valuable companion tool for improving patient outcomes.

Addition of darolutamide to first line treatment of metastatic castration-resistant prostate cancer (mCRPC): A randomized open label phase II trial (SAKK 08/23).

Journal of Clinical Oncology Ursula Vogl, Katrin Eckhardt, Katrin Gobat et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps280

TPS280 Background: The implementation of androgen-receptor pathway inhibitors (ARPI) +/- docetaxel (doce) in addition to androgen deprivation therapy (ADT)in metastatic hormone sensitive prostate cancer (mHSPC) has limited the therapeutic options in the mCRPC setting. In the SAKK 08/16 trial, darolutamide (daro) maintenance demonstrated prolonged radiographic progression-free survival (rPFS) compared to placebo in patients (pts) with mCRPC who had received prior ARPI, and did not progress during taxane therapy. This benefit was more pronounced in pts with a response to the prior ARPI. Continuing enzalutamide in addition to doce versus a switch to doce alone after progression on enzalutamide in later line mCRPC has been demonstrated to prolong PFS in a phase 3 trial. The continued maximal androgen-receptor (AR) blockage in the mCRPC first-line setting in addition to a standard of care could potentially control persistent AR-pathway sensitive clones. Daro is an optimal drug for the use as ARPI maintenance because of its favourable safety profile and a low potential for drug-drug interactions.We hypothesize that the addition of daro to a first-line SOC in mCRPC in pts with a prior long response to ADT and ARPI in mHSPC improves rPFS. Methods: SAKK 08/23 is an international open-label randomized phase 2 trial enrolling pts with ECOG 0-2 having progressed to mCRPC with a response to prior ADT-ARPI combination for at least 18 months showing at least a 50% PSA response or partial remission according to RECIST. Pts must not have received treatment for mCRPC. Pretreatment with doce in mHSPC is allowed. Patients will be randomized 1:1 to receive physician’s choice standard of care (SOC: doce, cabazitaxel, 177 lutetium-PSMA, radium-223 or olaparib) or SOC with daro. Treatment with daro will be continued until progression according to PCWG3. Stratification factors include country and treatment with taxanes versus radium-223 versus 177 lutetium-PSMA vs olaparib. The primary endpoint is rPFS. Secondary endpoints include overall survival, time to symptomatic/clinical progression, event-free survival, time to PSA progression by PCWG3, objective response rate according to RECIST, PSA response and PSA response duration. Without daro we expect a median rPFS of 6 months for taxanes, radium-223 and Olaparib and 8 months for 177 lutetium-PSMA. Assuming a three months increase in median rPFS with the addition of daro 121 events are needed (one-sided type I error of 10%, power of 80%) which leads to a sample size of 162 patients (including 10% dropout after one year). The trial will enroll pts in Switzerland and Spain. Accrual to the study is currently ongoing. Clinical trial information: NCT06401980 .

The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology Qian Wang, Hong Zeng, Jindong Dai et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.78

78 Background: The depth reduction in prostate-specific antigen (PSA) levels serves as a prognostic indicator for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) undergoing treatment with abiraterone. However, the potential impact of the duration of PSA level depth reduction on prognosis remains uncertain. Methods: We conducted a comprehensive review of data from 153 high-risk mHSPC patients undergoing first-line abiraterone therapy. The group analysis was conducted based on the alterations in PSA levels during abiraterone therapy. Kaplan-Meier survival curves and Cox proportional hazards regression analysis were used to evaluate the association between the trend and duration of PSA decline and treatment outcomes, which include PSA progression-free survival (PSA-PFS), radiographic progression-free survival (rPFS), and overall survival (OS). Results: Among the 153 patients treated, 85 exhibited a minimum PSA level of less than 0.2 ng/ml, 48 had a minimum PSA level ranging from 0.2 to 0.4 ng/ml, and 20 presented with a minimum PSA level exceeding 4 ng/ml.During abiraterone treatment, the lowest PSA level of <0.2 ng/ml was significantly associated with improved mPSA-PFS (51.0 vs. 18.5 vs. 6.9 months, P < 0.0001), mrPFS (52.0 vs. 24.3 vs. 10.3 months, P < 0.0001), and mOS (NR vs. 48.5 vs. 28.1 months, P < 0.0001). A reduction in PSA levels exceeding 90% was correlated with enhanced patient survival outcomes; additionally, a baseline PSA level of <80 ng/ml at the initiation of abiraterone therapy significantly improved patients' mPSA-PFS (43 .1 vs .26 .0 months, P=0 .01), mrPFS (46 .8 vs .27 .5 months, P=0 .01), and mOS (NR vs .43 .8 months, P=0.03).In the cohort with the lowest PSA levels (PSA < 0.2 ng/ml), achieving a PSA level of less than 0.2 ng/ml within six months and maintaining this level for over ten months significantly enhanced clinical outcomes, as evidenced by mPSA-PFS (NR vs. 26.9 months, P < 0.0001), mrPFS (NR vs. 27.5 months, P < 0.0001), and mOS (NR vs. 44.4 months, P < 0.0001). Cox regression analysis indicated that achieving a PSA level of less than 0.2 ng/ml within six months, sustaining this level for more than ten months, along with age and initial PSA at diagnosis were independent prognostic factors. Conclusions: In mHSPC patients undergoing first-line abiraterone treatment, a sustained improvement in PSA levels serves as an indicator of therapeutic response, while the rate and depth of PSA decline, along with its duration, are critical prognostic determinants.

Identification of metabolism-related subtypes and feature genes of pre-eclampsia

Scientific Reports Zhihui Xiong, Hailian Guan, Shuping Pei et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89140-8

Chronic obstructive pulmonary disease mortality risk in renal cell carcinoma: A population-based study from 1992-2021.

Journal of Clinical Oncology Oboseh John Ogedegbe, Olanipekun Lanny Ntukidem, Sakshi Bai et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.450

450 Background: Renal Cell Carcinoma (RCC) is one of the most common malignancies in the United States, with about 82000 new cases and 15000 deaths each year. Over the years, RCC mortality rates have been on a downward trend, and this is attributable to cutting-edge research and treatment modalities; however, non-cancer deaths continue to have an increasing trend. Chronic Obstructive Pulmonary Disease (COPD) plays a significant role in this trend. We holistically evaluated the COPD mortality risk in patients with RCC. Methods: We utilized the Surveillance, Epidemiology, and End Results (SEER) database to retrieve cases of RCC with mortality secondary to COPD from 1992 to 2021. The histologic code for RCC in the SEER database is 8312/3, which is part of the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). We then obtained the standardized mortality rates (SMR) and absolute excess risk (AER). Results: We compared the COPD mortality risk of each group to the general US population and noted significantly increased COPD SMRs. Patients with non-COPD causes of death and patients with unknown age, race and cancer stage were excluded. Regarding race, Non-Hispanic American Indians had the highest risk of COPD mortality (SMR 15.30, CI 3.16-44.71, AER 1029.25), followed by Non-Hispanic Asian/Pacific Islanders (SMR 8.67, CI 5.22-13.55, AER 1781.62), then Hispanics (SMR 3.67, CI 2.63-4.97 994.43), Non-Hispanic Whites (SMR 2.69, CI 2.44-2.95, AER 788.19), Non-Hispanic Blacks (SMR 2.33, CI 1.67-3.16, AER 648.94). Based on cancer stage, distant had the highest risk of COPD mortality (SMR 16.65, CI 9.70-26.65, AER 3985.35) while regional had relatively the lowest risk (SMR 3.62, CI 2.18-5.65, AER 1174.61) with localized (SMR 4.00 CI 3.37-4.72, AER 1572.98). In terms of age, patients aged 40-59 years had an SMR of 5.33 (CI 4.28-6.56, AER 619.66), 60-79 years had an SMR of 2.73 (CI 2.45-3.03, AER 838.76), while 80 years and above had an SMR of 2.00 (CI 1.63-2.43, p<0.05, AER 1261.89). Conclusions: We evaluated the extent of the risk of COPD-related deaths in RCC patients. Compared to the general United States population, patients with RCC have a higher risk of COPD mortality. Therefore, there is a need to improve primary and secondary preventive modalities and modify risk factors in this subset of patients to reduce morbidity and mortality.

Determining lung cancer screening eligibility in a surgically treated urothelial carcinoma population: Making the case for linking bladder cancer screening to lung cancer screening.

Journal of Clinical Oncology Aman Arora, Alexei Kopelevich, Serena Ly et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.875

875 Background: Bladder cancer is the 10th most common cancer globally, with 573,278 cases reported in 2020. Tobacco consumption is a major risk factor; smokers have a 3x higher risk of bladder cancer compared to non-smokers. Tobacco consumption is also a risk factor for lung cancer, and current guidelines recommend screening high risk patients. While screening for bladder cancer in the general population is not recommended, screening high-risk bladder cancer populations may be beneficial. We hypothesize that linking bladder cancer screening to lung cancer screening may have higher yield than general population screening and enable earlier bladder cancer diagnosis. Methods: We performed a retrospective review of patients at a single-institution that underwent surgical treatment for urothelial carcinoma (TURBT, ureteroscopy, ureterectomy, nephroureterectomy, or cystectomy) by a single urologic-oncologist from October 2022 to June 2024. Patients were initially referred for microscopic/gross hematuria, badder/upper tract mass, or known urothelial cancer. We collected patient demographics, smoking history and imaging/surgical pathology. We aimed to determine the eligibility of these patients for lung cancer screening programs. Secondary outcomes included rates of lung cancer screening and lung cancer diagnosis. Results: We identified 76 patients with a urothelial carcinoma diagnosis. 87% had bladder cancer and 13% had UTUC. 48 (63%) patients were either current or former smokers, and the mean pack year history was 24 pack years. Of those patients, 14 (29%) met the criteria for lung cancer screening guidelines (ages 50-80, at least a 20 pack year smoking history, and current smoker or quit within 15 years); only 1 patient (7%) had received a screening low-dose CT Chest for lung cancer screening. Out of these 14 patients, 11 (79%) had a concerning finding on CTU. Conclusions: Our analysis highlights that lung cancer screening uptake remains low. In our cohort, 29% met lung cancer screening guidelines at the time of diagnosis. In this high risk population, 79% had concerning findings on CTU. While our results are promising and establish a potential rationale for linking bladder cancer screening to lung cancer screening due to their higher inherent risk, future prospective studies are needed to demonstrate utility and benefit. Patient demographic information. No Smoking History (N = 28) Smoking History (N = 48) Overall (N = 76) Age, Mean (SD) 72.5 (12.2) 72 (9.9) 72.2 (10) Sex (%) Male 20 (71.4%) 35 (72.9%) 55 (72.4%) Female 8 (28.6%) 13 (27.1%) 21 (27.6%) Gross Hematuria Upon Presentation 12 (42.9%) 36 (75.0%) 48 (63.2%) Concerning CTU Findings 14 (50.0%) 31 (64.5%) 45 (59.2%) Taking Blood Thinners 11 (39.2%) 18 (37.5%) 29 (38.2%) CAD/Afibb/Stroke/PE 13 (46.4%) 19 (39.6%) 32 (42.1%) HTN/DM 17 (61%) 25 (52%) 42 (55.2%)

NSD2 inhibition as a therapeutic approach for treatment-induced neuroendocrine prostate cancer.

Journal of Clinical Oncology Lan Xu, J Erin Flynt, Sanjana Miskin et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.198

198 Background: Trans-differentiation from adenocarcinoma to neuroendocrine histology is a major treatment-induced resistance mechanism against androgen receptor pathway inhibitors (ARPI) in castration-resistant prostate cancer (CRPC). With increased use of ARPI in the clinic, neuroendocrine prostate cancer (NEPC) constitutes 15~20% of CRPC. The histone H3 K36 di-methyltransferase NSD2 has recently been shown to be a driver of the adeno-to-neuroendocrine trans-differentiation. The level of NSD2 expression is markedly increased in AR(-) NEPC compared to AR(+) CRPC and correlates with a poor disease outcome. Furthermore, genetic depletion of NSD2 has been shown to reverse AR(-) NEPC to an AR(+) adenocarcinoma phenotype and re-sensitize the prostate cancer cells to enzalutamide treatment. Methods: K36 Therapeutics has developed a selective NSD2 inhibitor KTX1001 that is currently undergoing clinical evaluation in multiple myeloma (NCT05651932). Dose proportional pharmacokinetics and on-target pharmacodynamics of KTX1001 have been observed as well as an excellent safety profile in patients. Here we have investigated whether pharmacological inhibition of NSD2 reverses AR(-) NEPC to AR(+) adenocarcinoma in preclinical models. Results: In the NEPC cell line NCI-H660, KTX1001 treatment led to a significant change in the epigenome landscape, resulting in reduced expression of neuroendocrine markers SYP, CHGA and FOXA2 and concomitant upregulation of the adenocarcinoma markers AR, NKX3.1 and KLK3. These observations are consistent with a lineage change from AR(-) NEPC to AR(+) adenocarcinoma. We further investigate this in vivo using a NEPC patient-derived xenograft model. Indeed, treatment with our selective NSD2 inhibitor resulted in pronounced upregulation of the Hallmark Androgen Response gene signature, suggesting restoration of the AR-signaling pathway. Moreover, Hallmark E2F and Myc signatures, which are known to be elevated in NEPC cells, were markedly downregulated after NSD2 inhibitor treatment. These observations suggest a significant change in NEPC lineage identity towards AR(+) adenocarcinoma. Conclusions: These data support our hypothesis that NSD2 inhibition can reverse NEPC to AR(+) adenocarcinoma lineage and restore sensitivity to standard-of-care ARPI. Given these mechanistic insights and the safety profile observed with our NSD2 inhibitor in the clinic, evaluation of NSD2 inhibition in NEPC patients is warranted.

Establishing reproductive seasons for the conservation of the critically endangered Kashmir red deer Cervus Hanglu

Scientific Reports Tanushree Srivastava, Javaid Hameed, Vinod Kumar et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89244-1

Survival outcomes of testicular cancer (TC) in Hispanic men based on analyses from the National Cancer Database (NCDB).

Journal of Clinical Oncology Eun-mi Yu, Hongkun Wang, Jeanny B. Aragon-Ching Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.622

622 Background: The incidence of TC among Hispanic men has been rising, as reported in our analysis of patients in the United States (Yu et al., JCO 2024 42 (4):503). We sought to determine the survival outcomes in Hispanic men based on data obtained from the National Cancer Database (NCDB). Methods: We extracted patient-level data from the NCDB and identified the incidence, demographics, treatment patterns, and outcomes in Hispanic men with TC diagnoses (non-seminoma, NS; seminoma, S) from 2004 to 2020. Results: There were a total of 89550 patients (pts) in the database. Median age at diagnosis was 37 years and 29 years for S and NS pts, respectively. There were 11005 (12.3%) TC pts designated as Hispanic (H), of whom 5396 and 5609 had S and NS TCs, respectively. In contrast, there were a total number of 74350 non-Hispanic (NH) patients with TC; n = 43629 with S, n = 30721 with NS. The majority of H pts had a Charlson-Deyo score of 0 (94.2%). Less than half of H pts had private insurance (48.8%) compared to three-quarters of NH patients (75.1%). 19.6% of H pts were diagnosed with stage II & III TC (compared to 15.8% in NH pts). Pts were treated at academic/research centers in 6.6% of H pts versus 10.8% in NH pts. For S pts, radiation was utilized in 19.4% of H pts vs 25.8% in NH pts, chemotherapy utilized in 28.3% H pts vs 24.4% in NH pts, whereas chemotherapy for NS pts was utilized in 60.1% in H pts vs 53.4% in NH pts. Overall Survival (OS) was not significantly different in S pts for H pts vs NH pts (Log-rank p = 0.066), but among NS pts, H patients did worse compared to NH pts (Log-rank p < 0.001) although OS differences were seen in pooled analyses of S and NS pts (log-rank p < 0.001). Conclusions: Our analysis reports on the treatment patterns and survival of Hispanic men with TC. Survival appears to be worse for Hispanic patients with non-seminoma compared to non-Hispanic patients, but outcomes for seminoma are similar. We also noted slight differences in patterns of treatment receipt for seminoma versus non-seminoma in Hispanic men which may have to do with stage at diagnosis and access to care.

Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial.

Journal of Clinical Oncology Viktor Grünwald, Daniel Keizman, Jens Bedke et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.531

531 Background: L+P significantly improved efficacy vs sunitinib in treatment-naïve pts with aRCC in the CLEAR trial (Motzer 2021). We report data from further analyses on the impact of tumor burden at the time of progression and shifts in IMDC scores in the L+P arm of the CLEAR study. Methods: Study design has been reported (Motzer 2021). Data cutoff for analyses was July 31, 2022 (median follow-up: ~4 years; Motzer 2024). Data herein are limited to the L+P arm of CLEAR. Medians for survival from either progression or randomization (i.e., overall survival) were estimated by Kaplan-Meier method, and 95% CIs were estimated via generalized Brookmeyer and Crowley method. Survival was assessed according to percent changes from baseline in target lesion diameters of pts at progression (on L+P) by tertiles (T1: ≤-61%; T2: >-61%-≤-34%; T3: >-34%-≤51%). Changes in IMDC score from baseline were reported at 6 months to assess treatment impact on prognosis. Results: Pts with a larger percentage decrease in sums of target lesion diameters at progression had longer median survival (months [95% CI]) from time of progression vs pts with smaller percentage decreases in tumor size (T1 [n=59], 35.6 [28.4-39.2]; T2 [n=58], 24.4 [15.5-34.5]; T3 [n=59], 20.2 [16.4-26.9]). Similar trends were observed with overall survival (from randomization; T1, not estimable [49.9-NE]; T2, 43.0 [33.0-NE]; T3, 31.5 [22.4-34.4]). Most pts, irrespective of tumor shrinkage at progression, received subsequent systemic anticancer medication during survival follow-up (T1: 63%; T2: 59%; T3: 71%). Pts received an anti-VEGF therapy (46%; 45%; 59%) as their first subsequent medication more frequently than any other medications. The most frequently used anti-VEGF therapies were cabozantinib (22%; 29%; 29%), sunitinib (12%; 3%; 20%), and axitinib (7%; 3%; 8%). At 6 months, IMDC score stayed the same or decreased from baseline in most pts; ≤10% of pts had increases in IMDC score, regardless of score at baseline (Table). Conclusions: Pts in the L+P arm with lower disease burden at progression showed improved prognosis, highlighting the importance of deep tumor response when considering treatment sequence. IMDC risk scores were typically constant or improved in pts treated with L+P; data are limited by missing pts. Clinical trial information: NCT02811861 . L+P arm IMDC score at 6 months, n (%) Baseline IMDC score a Decreased by ≥1 points Remained constant Increased by 1 point Increased by ≥2 points Missing b 0 (n=110) NA 84 (76) 9 (8) 2 (2) 15 (14) 1 (n=137) 25 (18) 82 (60) 8 (6) 2 (1) 20 (15) 2 (n=72) 34 (47) 18 (25) 5 (7) 1 (1) 14 (19) 3 (n=26) 18 (69) 0 0 0 8 (31) 4 (n=5) 4 (80) 0 0 0 1 (20) 5 (n=1) 1 (100) 0 0 0 0 Total (n=355) 84 (24) 186 (52) 22 (6) 5 (1) 58 (16) a 4 pts had a missing score at baseline. b IMDC prognostic score was derived based on total risk score from 6 prognostic factors at baseline and month 6 (+/- 2 weeks).

A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact.

Journal of Clinical Oncology Junlong Zhuang, Shun Zhang, Xuyu Zhang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps292

TPS292 Background: Approximately 10% - 15% of patients with metastatic hormone sensitive prostate cancer (mHSPC) harbor loss-of-function mutations in homologous recombination repair (HRR) genes. Although olaparib plus abiraterone and prednisone has significantly prolonged radiographic progression-free survival (rPFS) in metastatic castration resistant prostate cancer patients, there is a lack of evidence regarding the efficacy of this combination therapy in patients with mHSPC. Here, we report the updated analysis of PROact study, the first phase II trial to evaluate the effects of olaparib plus abiraterone and prednisone in mHSPC patients with HRR gene mutation. Methods: This was a single center, single arm, phase II trial (NCT05167175) conducted in male patients with mHSPC who had at least one HRR gene mutation ( BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD 51C, RAD51D and RAD54L ) as determined by tissue-NGS. Patients were administered olaparib 300 mg BID plus abiraterone 1000 mg QD and prednisone 5 mg QD. Previous treatment with new hormonal agent (NHA) was not allowed. The primary endpoint was 1-year radiographic progression-free survival (rPFS) rate per PCWG3-modified RECIST 1.1 by investigator assessment. The secondary endpoint included prostate-specific antigen (PSA) response rate, objective response rate (ORR), and adverse events. Safety and efficacy data with a median follow-up of 9.5 months have been reported. Here, we present the updated efficacy data categorized by gene. Results: Thirty patients were enrolled, all of whom had de novo mHSPC, consisting of 30% (9/30) with low-volume and 70% (21/30) with high-volume disease. As of the data cut-off (September 6, 2024), the median follow-up duration was 14.0 months. 13 patients had measurable disease; the confirmed ORR was 84.6% (11/13). One patient with ATM mutation achieved complete response. Ten patients obtained partial response, including four with BRCA2 , two with ATM , two with CDK12 , one with RAD51B mutations and one with co-mutation of three pathogenic genes. Furthermore, two patients harboring BRCA2 mutation experienced progressive disease (Table). Clinical trial information: NCT05167175 . Gene by gene efficacy evaluation. HRR mutation Totally number RECIST assessment CR PR PD BRCA2 11 6 0 4 2 CDK12 7 2 0 2 0 ATM 6 3 1 2 0 PALB2 2 0 - - - CHEK2 1 0 - - - RAD51B 1 1 0 1 0 RAD51D 1 0 - - - CDK12, CHEK2, RAD51B 1 1 0 1 0

Author Correction: Exploring online public survey lifestyle datasets with statistical analysis, machine learning and semantic ontology

Scientific Reports Ayan Chatterjee, Michael A. Riegler, Miriam Sinkerud Johnson et al. Feb 10, 2025 DOI: 10.1038/s41598-025-86904-0

Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC).

Journal of Clinical Oncology Alicia K. Morgans, Maelys Touya, Nader N. El-Chaar et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.354

354 Background: PSADT is one of the strongest predictors of outcomes in patients (pts) with BCR PC and a criterion for HR BCR definition. As such, it is crucial to determine whether physicians are aware of pts’ PSADT and how this influences Tx in routine practice. We compared Tx patterns in pts with HR BCR whose PSADT was known (kPSADT) or unknown (uPSADT) by the physician. Methods: This physician-abstracted chart review used data of pts with HR BCR from the Cardinal Health Oncology Provider Extended Network (2018–2020) in the US. HR BCR definition: PSADT ≤9 months (mo) with PSA at or above the threshold per the EMBARK trial. Follow-up was from the index date (date on which HR BCR definition was met) until disease progression, last follow-up, or death through 2022. Physicians reported PSADT in case report forms (CRFs) using doubling time from labs, clinical judgement, or an online calculator (kPSADT). If not provided in the CRF, PSADT was calculated retrospectively based on PSA values up to the index date that the physician had entered in the CRF (uPSADT). We analyzed time to treatment after index via the Kaplan–Meier method. Results: Among 284 pts with HR BCR, median time from initial PC diagnosis to the end of follow-up was 39.1 mo; most pts had kPSADT). There were differences between in age, time from localized PC diagnosis to BCR, Gleason score, and PSA at initial diagnosis and at BCR (Table). A higher proportion of pts with uPSADT had a fast PSADT (≤3 mo) (61% vs 20%, P < 0.001). A higher proportion of pts with kPSADT (64%) vs uPSADT (17%) received Tx within 60 days after index, with a shorter median time to Tx (1.0 vs 6.7 mo; HR: 3.4, 95% CI: 2.6–4.4, P < 0.0001). Conclusions: Most physicians did not know their pts’ PSADT. Even though pts with HR BCR PC who had kPSADT were older and had slower PSADT, they were over three times more likely to receive Tx vs pts with uPSADT. The results suggest that many pts with HR BCR PC may be missed in clinical practice, which limits these pts’ opportunity to receive guideline-concordant Tx to delay progression. Characteristics of index kPSADTn = 104 uPSADTn = 180 P value Age (years), mean (SD) 70.0 (7.6) 65.6 (7.0) <0.001 Primary definitive PC Tx, n (%) Radiotherapy 28 (27) 51 (28) Prostatectomy 76 (73) 129 (72) Time from localized PC diagnosis to BCR ≤2 years, n (%) 97 (93) 143 (79) 0.002 Gleason score ≥8, n (%) 76 (73) 81 (45) <0.001 PSA before initial localized PC diagnosis (ng/mL), median (IQR) 9.0 (6.7) 7.9 (8.6) 0.019 PSA at BCR (ng/mL), median (IQR) 3.4 (9.0) 2.6 (2.8) <0.001

Trends in cardiovascular mortality in older adults with malignant neoplasms of male genital organs in the United States from 1999 to 2020.

Journal of Clinical Oncology Mohammad Abu-Tineh, Eeshal Fatima, Wajeeh Hassan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.29

29 Background: The American Cancer Society estimated that 1.9 million new cancer cases were identified in 2021, comprising 260,210 newly diagnosed male genital neoplasm cases. Prostate cancer is considered the second leading cause of cancer-related mortality among men in the United States (US). Cardiovascular events are commonly observed in patients receiving androgen deprivation therapy or platinum-based chemotherapy, fundamental treatments for malignant male reproductive organ tumors. Therefore, the objective of our study is to evaluate the temporal and regional trends of cardiovascular mortality in men 55 years or older with malignant neoplasms of the male genital organs in the US from 1999 to 2020. Methods: We used the death certificate data from the Centers for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database to determine crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) per 100,000 individuals. Joinpoint regression calculated the annual percent change (APC) and average annual percent change (AAPC) in AAMR. Results: A total of 109,970 cardiovascular-related deaths occurred in older adults with neoplasms of male genital organs in the US from 1999-2020, with an overall AAMR of 18.55. A gradually decreasing trend in mortality was observed until 2003 (APC -4.43, 95% CI = -5.33 to -3.16), followed by a sharp decline until 2013 (APC -6.89, 95% CI = -7.36 to -6.62), and another gradual decline till 2018 (APC -3.12, 95% CI = -4.21 to -1.99). However, from 2018 to 2020, a drastic increase was observed (APC 6.03, 95% CI = 3.41 to 7.96). Individuals older than 85 showed the highest mortality (130.17), followed by those aged 75 to 84 (31.79). Among racial groups, the highest AAMR was seen in Non-Hispanic (NH) Black or African Americans (33.87), followed by NH Whites (18.14), NH American Indians or Alaskan Natives (13.26), Hispanics (11.50), and NH Asians or Pacific Islanders (7.98). Among census regions, the highest and lowest mortality were observed in the Western region (20.04) and Southern region (16.34), respectively. While urban areas reported a significantly higher number of deaths (88,263) compared to rural areas, the AAMR was higher in rural areas (20.20) than in urban areas (18.16). Conclusions: An overall decreasing trend of cardiovascular mortality was observed among older adults with malignant neoplasms of male genital organs from 1999 to 2020 in the US; however, the sharp rise from 2018 to 2020 is important to consider. There were notable disparities in mortality among NH Blacks or African Americans, males over 85, and residents of rural and Western regions. The results of our study highlight the necessity of providing cardiovascular treatment to cancer patients at earlier stages, particularly in vulnerable subgroups, necessitating close collaboration between oncologists and cardiologists.

Combined analysis of circulating tumor cells and PSMA imaging metrics to predict efficacy of <sup>177</sup> Lu-PSMA-617 in metastatic prostate cancer.

Journal of Clinical Oncology Yoshiyuki Miyazawa, Arda Könik, Zoe Guan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.215

215 Background: Radioligand therapy targeting prostate-specific membrane antigen (PSMA), such as 177 Lu-PSMA-617, has demonstrated clinical efficacy in PSMA-PET-positive metastatic castration-resistant prostate cancer (mCRPC). However, not all PSMA-positive mCRPC patients benefit from this therapy, highlighting the need for novel biomarkers to predict treatment response. We aimed to evaluate whether molecular analysis of circulating tumor cells (CTCs) could provide predictive biomarkers of 177 Lu-PSMA-617 therapy. Methods: In this single-institution biomarker study, male patients with PSMA-PET-positive mCRPC scheduled to begin treatment with 177 Lu-PSMA-617 were enrolled. Informed consent was obtained (DF-HCC 13-416). CTCs were isolated from blood samples collected prior to the initiation of 177 Lu-PSMA-617 therapy using a microfluidic device (CTC-iChip). Half of the CTCs from each patient were immunostained with antibodies against cytokeratin, EpCAM, and PSMA and counterstained with CD45 to exclude leukocytes. The stained CTCs were imaged using a Vectra Polaris multispectral microscope. The fluorescence intensity of PSMA in each CTC was categorized into four levels (3+, 2+, 1+, 0). The remaining CTCs were analyzed using droplet digital polymerase chain reaction (ddPCR) to profile the expression of prostate-specific genes, the androgen receptor splice variant AR-V7 , and neuroendocrine genes. CTC analyses and pre-treatment PSMA-PET imaging metrics were compared with clinical outcomes. Radiographic progression-free survival (rPFS) was evaluated using Kaplan-Meier analysis and log-rank tests. Results: Blood samples from 24 enrolled patients were analyzed, with a median follow-up of 7.5 months. Median age was 71.5 years (range 53-83). Median CTC count was 5.9 cells/7.5mL blood. Patients with high CTC count (&gt;5.85 cells/7.5 mL) and presence of PSMA-negative CTCs had worse rPFS compared to others, although the difference was not statistically significant (median 86 vs. 393 days, log-rank p = 0.0840). Patients who were AR-V7 -positive before treatment had significantly shorter rPFS compared to AR-V7 -negative patients (median 67 vs. 393 days, log-rank p = 0.0031). Additionally, DLL3 -positive patients had significantly shorter rPFS than DLL3 -negative patients (median 109 days vs. 402 days, log-rank p = 0.0348). Using machine learning, a predictive model was developed incorporating the following factors: mean SUV, CHGA , ARV7 , STEAP2 , DLL3 , AGR2 , and E2F1 . This model demonstrated a high predictive accuracy for treatment outcomes (Low-risk group: median survival 447 days vs. High-risk group: 109 days, log-rank p = 0.0002). Conclusions: The molecular analysis of CTCs in combination with PSMA PET imaging metrics may be useful for predicting the therapeutic efficacy of ¹⁷⁷Lu-PSMA-617 treatment, and warrants validation in additional cohorts.

Data - Driven Approaches for Detecting Autism Spectrum Disorder : A Comprehensive Review

International Research Journal of Computer Science Dr.Geeta R.Bharamagoudar, Sahana Bisalapur Feb 10, 2025 DOI: 10.26562/irjcs.2025.v1202.01

Autism Spectrum Disorder (ASD) is a neuro developmental ailment that affects significant portion of the global population, with symptoms including cognitive and behavioural impairments. Early and precise detection is critical for effective intervention and helps to minimize the overall impact of it, however, the traditional methods of ASD detection are time-consuming and dependent on clinical expertise. In recent years, Data Mining combined with Machine Learning (ML) and Deep Learning (DL) techniques have shown huge potential in refining the accuracy, speed, and efficiency of ASD diagnosis. This paper reviews the application of these advanced technologies, particularly the use of neuroimaging data such as fMRI, EEG, and MRI, in diagnosing ASD. By leveraging the automated feature extraction technique of these methods, predictive algorithms, and end-to-end learning, ML and DL models have demonstrated the potential to identify complex patterns in brain activity, offering insights into potential biomarkers for ASD. Several approaches have been presented to augment the detection accuracy where conventional machine learning methods have focused on data mining approaches along with image data. However, the accuracy of these systems for imaging data is affected due to complex brain patterns therefore; deep learning based methods have gained popularity because of their robust pattern learning methods. Thus, the exploitation of ML and DL with neuroimaging tools has the potential to enhance early diagnosis, paving way for timely interventions and enhanced results for patients with ASD. This review also highlights the challenges and future prospects of applying these technologies to ASD diagnosis, plus the need for large-scale datasets and the development of universally applicable frameworks.

Assessing HIV transmission knowledge and rapid test history among the general population in Iran

Scientific Reports Keyvan Karimi, Yosra Azizpour, Maryam Shafaati et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88844-1

Assessment of cardiovascular (CV) toxicity by providers in advanced prostate cancer (PCa) patients (pts) on novel hormonal therapy (NHT).

Journal of Clinical Oncology Dalia Kaakour, Eunah Cho, Aya Ozaki et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.125

125 Background: Addition of NHT, including Abiraterone, Enzalutamide, Apalutamide, and Darolutamide, to androgen deprivation therapy in patients with advanced PCa demonstrated improved survival in large randomized controlled trials. However, NHTs are associated with development of metabolic syndrome and CV toxicity. Treatment related adverse events (TRAEs) may include hypertension (HTN), hyperglycemia, atrial fibrillation, myocardial infarction (MI), congestive heart failure (CHF), and stroke. As such, monitoring for these toxicities by treating providers is essential. Cardio-oncology is an emerging field that addresses CV needs of cancer pts and fosters collaboration between oncologists and cardiologists. Methods: This is a retrospective analysis of 92 pts with advanced PCa, who initiated an NHT in 2022 at the University of California Irvine. Medical records were analyzed for various metrics relating to CV risk assessment performed by treating providers. Results: Pts of 11 different providers, including medical and urologic oncology, were examined. Characteristics of the study population at NHT start are described (Table). Within specific study population subgroups outlined, corresponding provider interventions within 3 months of NHT start are also listed. Conclusions: In this dataset of pts with pre-existing features of metabolic syndrome and CV risk factors at NHT start, only a minority had screening for hyperglycemia, hyperlipidemia, and cardiac dysfunction as well as had counseling about appropriate nutrition or referred to cardiology. Provider education about NHT-related TRAEs and emphasis on early screening for CV toxicity is key. Characteristics of the study population and corresponding provider interventions. Pt characteristic at NHT start % of pts Had lipid panel checked (%) Had hemoglobin A1C checked (%) Seen by cardiology before NHT start (%) Referred to cardiology post NHT start (%) Had documented counseling about nutrition (%) Had echocardiogram (%) Body mass index (BMI) 25.0 - 29.9 50.0 26.1 32.6 23.9 6.5 10.9 23.9 BMI ≥30 21.7 40.0 40.0 35.0 0.0 10.0 30.0 Former or active smoker 41.3 42.1 42.1 23.7 5.3 5.3 34.2 Hx of HTN 69.6 29.7 42.2 29.7 3.1 7.8 23.4 On ≥2 blood pressure (BP) agents 29.3 48.1 55.6 40.7 3.7 3.7 40.7 Hx of hyperlipidemia 64.1 30.5 35.6 28.8 1.7 8.5 25.4 On a statin 51.1 31.9 34.0 29.8 2.1 8.5 27.7 Hx of MI 20.7 36.8 36.8 52.6 0.0 5.3 31.6 Hx of CHF 9.8 44.4 77.8 55.6 11.1 0.0 55.6 Hx of arrhythmia 20.7 42.1 57.9 57.9 0.0 0.0 31.6 Hx of stroke 8.7 25.0 62.5 37.5 0.0 0.0 25.0 Hx of diabetes mellitus (DM) 34.8 34.4 50.0 37.5 3.1 9.4 31.3 On a non-insulin DM agent 38.0 28.6 37.1 28.6 2.9 14.3 25.7 On insulin for DM 14.1 23.1 61.5 23.1 0.0 7.7 15.4

Clinical outcomes for radiographic node-positive prostate cancer following definitive radiotherapy.

Journal of Clinical Oncology Jade Dodge, Lillian A Boe, Kevin Boehm et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.352

352 Background: The incidence of regional lymph node metastases at diagnosis is approximately 15%. Androgen deprivation therapy (ADT) with radiotherapy (RT) remains a standard treatment option, but long-term effects and outcomes are understudied. Methods: Data was retrospectively collected from 304 subjects with radiographic node-positive prostate cancer treated with RT from 2014-2024. Covariates include use of androgen receptor signaling inhibitors (ARSI), use of brachytherapy boost to primary disease in prostate, pre-RT PSA, and Gleason Score (GS). Endpoints included biochemical progression (bPFS), distant metastases free survival (DMFS) and overall survival (OS). Kaplan-Meier method, log rank test, univariate (UVA) and multivariate regression analyses (MVA) were used for time to event endpoints. Results: Patient features are summarized in table. 48% of patients had ECOG 0. On MVA, GS 9-10 was significantly associated with worse OS (HR 2.26, 95%CI 1.15 – 4.43, p=0.02), DMFS (HR 2.37, 95%CI 1.32 – 4.24, p&lt;0.01) and bPFS (HR 2.10, 95%CI 1.23 – 3.59, p&lt;0.01). Worse performance status was associated with significantly worse OS (HR 3.14, 95%CI 1.35 – 7.29, p&lt;0.01), DMFS (HR 2.03, 95%CI 0.95 – 4.35, p=0.07) and bPFS (HR 2.01, 95%CI 0.99 – 4.07, p=0.05). Radiation boost dose to involved lymph nodes was significantly associated with OS (p=0.03) and DMFS (p=0.03) but not bPFS. There were no other statistically significant associations on MVA. There was no significant association on UVA between pre-radiation maximum PSA and OS, DMFS, or bPFS. Conclusions: In this cohort of patients treated with ADT and definitive RT, 5-year DMFS was 67%. Gleason score and age were the strongest prognostic features. There was no significant association, but there was numerically higher survival seen with use of ARSI or brachytherapy boost. Future work includes characterizing patterns of care and failure to help optimize management. Characteristics and univariable regression results for OS, DMFS, and bPFS using age and pre-RT PSA as continuous variables. N (%) 5yr OS HR (95%CI) p-value 5yr DMFS HR (95%CI) p-value 5yr bPFS HR (95%CI) p-value Age (continuous) Median age (IQR) 69 (64 – 75) 74% 1.04 (1.00 – 1.09) p=0.07 67% 1.02 (0.99 – 1.06) p=0.2 65% 1.02 (0.99 – 1.05) p=0.3 Gleason 8 156 (54%) 83% 74% 71% 9-10 135 (46%) 69% 2.05 (1.06 – 3.95) p=0.03 62% 2.17 (1.25 – 3.77) p&lt;0.01 60% 2.06 (1.22 – 3.49) p&lt;0.01 Brachytherapy Use Yes 86 (28%) 80% 0.60 (0.27 – 1.35) p=0.2 79% 0.62 (0.31 – 1.22) p=0.2 79% 0.61 (0.32 – 1.16) p=0.13 ARSI Use Yes 182 (60%) 78% 0.91 (0.50 – 1.64) p=0.7 67% 0.90 (0.54 – 1.50) p=0.7 67% 0.79 (0.48 – 1.29) p=0.3 Volume Nodal Boost – Below median Median (IQR) 16.1 cc (7.3 – 33.9) 76% 0.99 (0.54 – 1.80) p&gt;0.9 72% 0.93 (0.55 – 1.56) p=0.8 68% 1.05 (0.64 – 1.73) p=0.8 Volume of radiographically involved lymph nodes assessed as binary variable.